CRISPR Therapeutics and Vertex Pharmaceuticals received FDA approval for their gene therapy Casgevy for sickle cell disease.
1 report, 1 independent
Updated Jun 22
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
CRISPR Therapeutics and Vertex Pharmaceuticals received FDA approval for their gene therapy Casgevy for sickle cell disease.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
CRISPR Therapeutics
company in Basel, Switzerland
Nothing else this week.
-
Vertex Pharmaceuticals
American pharmaceutical company
- FDA
Related events
- CRISPR Therapeutics and Scribe Therapeutics presented at a Morgan Stanley conference, highlighting their competition in gene-editing therapeutics.
- CRISPR Therapeutics presented durability data on gene therapy at the European Society of Cardiology (ESC) Congress on August 28, 2026.
- FDA placed a clinical hold on a gene therapy involving Hunter.
- Solid Biosciences received FDA approval for a gene therapy trial on July 9, 2025.
- CRISPR Therapeutics is discussing commercial priorities and expanding treatment access into new markets with an investment bank.